Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover

Authors:

Morgan GJ, San Miguel J, Dhanasiri S, Lee D, Palumbo A, Facon T, Zaki MH, Yu X, Sternas LA, Jacques C, Weisel KC, Offner F and Dimopoulos MA.

Publication Type:

Conference Proceedings – Poster

Publication Name:

American Society of Clinical Oncology (ASCO) Annual Meeting

Citation:

Morgan GJ, San Miguel J, Dhanasiri S, Lee D, Palumbo A, Facon T, Zaki MH, Yu X, Sternas LA, Jacques C, Weisel KC, Offner F and Dimopoulos MA. Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, United States of America. 30 May – 3 June 2014. Poster 8593.


Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies